Buscar
Resultados de la búsqueda
- Efficacy and safety of the monoclonal antibody nimotuzumab plus FOLFOX vs. FOLFOX as first-line treatment of patients with unresectable, left-sided, metastatic colorectal cancer. Phase I/II
-
... Efficacy and safety of the monoclonal antibody nimotuzumab plus FOLFOX vs. FOLFOX as first-line treatment of patients with ... Nimotuzumab group (experimental): Monoclonal antibody nimotuzumab (200 mg, intravenously) + FOLFOX (FOLFOX4, FOLFOX6, or mFOLFOX6) ...
Clinical Trials - CIM - 12/08/2025 - 1:26pm
- Eficacia y seguridad del anticuerpo monoclonal nimotuzumab más FOLFOX vs. FOLFOX como primera línea de tratamiento de pacientes con cáncer colorrectal metastásico, del lado izquierdo, irresecable. Fase I/II
-
... Eficacia y seguridad del anticuerpo monoclonal nimotuzumab más FOLFOX vs. FOLFOX como primera línea de tratamiento de ... claves: Nimotuzumab, FOLFOX, CCRm, colon izquierdo, irresecable ...
Ensayos Clínicos - CIM - 12/08/2025 - 1:26pm
- Oncoxin-Viusid/Adenocarcinoma pancreático/Adultos/Fase II
-
... F., Reuter D, Edler L., and Mross K. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor ... et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with ...
Ensayos Clínicos - CATALYSIS - 23/07/2025 - 4:16pm
- Nimotuzumab in Esophagus premalignant lesions
-
... title: Nimotuzumab in the treatment of pre-malignant lesions of the esophagus. ... Nimotuzumab group (Experimental): Nimotuzumab plus Omeprazole. The Nimotuzumab be administered intravenously ...
Clinical Trials - CIM - 21/06/2024 - 11:09am
- Nimotuzumab en lesiones premalignas Esófago
-
... estudio: Nimotuzumab en el tratamiento de lesiones pre malignas de esófago. Estudio ... claves: nimotuzumab, Esófago Barret, lesiones premalignas, anticuerpo monoclonal, EGFR ...
Ensayos Clínicos - CIM - 21/06/2024 - 11:08am
- Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT)
-
... Title: Nimotuzumab in NSCLC Scientific title: ... histology NSCLC, treated with concurrent CT-RT plus Nimotuzumab vs concurrent CT-RT. Acronym of ...
Clinical Trials - CIM - 19/07/2023 - 3:22pm
- Nimotuzumab en Cancer de Pulmon de Celulas No pequenas (CPCNP) de histología epidermoides en estadios III inoperables, concomitante con Quimi-RadioTerapia (QRT)
-
... Nimotuzumab en CPCNP Título completo del ... III inoperables, tratados con QT-RT concurrente más Nimotuzumab vs QT-RT concurrente. Siglas ... Nimotuzumab en CPCNP concomitante con QRT ...
Ensayos Clínicos - CIM - 19/07/2023 - 3:21pm
- Safety and efficacy of VAXIRA® in advanced NSCLC patients not progressing after first line chemotherapy. Phase III.
-
... after first line-chemotherapy, treated with VAXIRA® or Nimotuzumab as switch maintenance therapy. ... while patient’s conditions allow it. Control group (Nimotuzumab): 200 mg in 250 ml of saline solution administered intravenously ...
Clinical Trials - CIM - 19/07/2023 - 3:20pm
- Eficacia y seguridad de VAXIRA® en pacientes con CPCNP en estadio avanzado no progresores a primera línea de quimioterapia. Fase III
-
... primera línea de quimioterapia, tratados con VAXIRA® o Nimotuzumab en terapia de mantenimiento de cambio. ... Cáncer de pulmón, Vacuna terapéutica, VAXIRA® , Nimotuzumab Identificador(es) del ...
Ensayos Clínicos - CIM - 19/07/2023 - 3:11pm
- Efficacy and safety of Jusvinza treatment in patients with acute respiratory distress syndrome. Phase II/III
-
... Tocilizumab), anti-IL-1 monoclonal antibody (eg Anakinra), Nimotuzumab or Itolizumab 6) Patient currently participating in another ...
Clinical Trials - CIGB - 02/05/2023 - 1:29pm